The N6-Methyladenosine mRNA Methylase METTL14 Regulates TLR4-mediated intestinal dysfunction in Parkinson’s Disease
Objective: The aim of this study is to explore the function and mechanism of RNA m6A modification in gut-derived inflammation of Parkinson's disease (PD). Background:…LRRK2 G2019S as a trigger of inflammatory signaling in patient-derived microglia
Objective: This study explores the inflammatory processes in leucine-rich repeat kinase 2 (LRRK2)- microglia carrying the G2019S mutation and determines their contribution to Parkinson’s disease…Protective effect and mechanism of TREM2 in Parkinson’s disease with cognitive impairment
Objective: this study explored whether TREM2 plays a protective role in PD with cognitive impairment by promoting the activation of DAM. Background: The latest research…Plasma biomarkers in iRBD patients serve as potential markers of early PD and motor severity
Objective: We aimed to investigate biomarkers of inflammation and neuroaxonal damage in people with isolated REM sleep behaviour disorder (iRBD) compared to controls, and understand…Montelukast as disease modifying treatment for Parkinson’s disease: a pilot study.
Objective: To assess safety and tolerability of high dose Montelukast as a possible disease modifying treatment for Parkinson’s disease. Background: Emerging evidence suggests that the…Preliminary Report on the efficacy of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson’s disease: Phase IIa double-blind, randomized controlled trial.
Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) delivered intravenously to slow the progression of…Preliminary Report on the Safety and Tolerability of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for Parkinson’s disease: Phase IIa double-blind, randomized controlled trial
Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) purified from bone marrow-derived from a healthy…Parkinson’s Disease and Chronic Inflammatory Demyelinating Polyneuropathy: Broadening the Clinical Spectrum of VCP Mutations?
Objective: Valosin-containing protein (VCP) mutation causes a multiorgan disease characterized by inclusion body myopathy, Paget disease and frontotemporal dementia, more rarely by Charcot-Marie-Tooth disease type…Baseline fluid biomarkers in a phase 2 clinical trial in Parkinson’s Disease
Objective: To evaluate baseline CSF and blood-based biomarkers of pathology in early-stage Parkinson’s Disease (PD) participants in the phase 2 clinical trial PASADENA. Background: Observational…GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson’s disease.
Objective: To investigate the effect of the structurally targeted allosteric regulator GT-02287 on rotenone-induced neurotoxic effects in a Parkinson’s disease animal model. Background: Mutations in…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 25
- Next Page »